A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 weeks of Treatment with Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis
Study identifier:322
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 weeks of Treatment with Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis.
Medical condition
Erosive Esophagitis
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole, Lansoprazole
Sex
All
Actual Enrollment
1000
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Dec 2002
Primary Completion Date: 01 Aug 2003
Study Completion Date: 01 Aug 2003
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Nexium | Drug: Esomeprazole 40mg once daily Other Name: Nexium |
| Active Comparator: 2 Prevacid | Drug: Lansoprazole 30mg once daily Other Name: Prevacid |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
